

# Sirolimus DEB in Coronary Bifurcation Lesions

NCT04896177

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shenzhen Salubris Pharmaceuticals Co., Ltd.
Enrollment	280 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Male or Female that ages 18-85 year old;
  - Having evidence of myocardial ischemia;
  - Voluntarily participates in this study and signs the informed consent form (ICF);
  - Sufficiently compliant with the study protocol and agreed to receive follow-up at 1 month  $\pm 7$  days, 6 months  $\pm 14$  days, 9 months  $\pm 30$  days, 12 months  $\pm 30$  days, and 24 months  $\pm 30$  days, of which angiography was required at 9 months  $\pm 30$  days;
  - Angiography confirmed as de novo bifurcation lesion with side-branch stenosis (diameter)  $\geq 70\%$ ;
- ... and 3 more (see full listing online)

### Exclusion (16)

- Women who is pregnant or lactating, or having a fertility plan within 1 year or are unwilling to take effective contraceptive measures;
  - Cardiogenic shock patients;
  - With hemorrhagic symptoms or active gastrointestinal ulcers, or previous stroke within 6 months, or who are expected to be unable to tolerate double-antibody therapy after interventional therapy;
  - ST-segment elevation myocardial infarction (STEMI) occurred within one week before enrollment;
  - With severe congestive heart failure or NYHA class c heart failure;
- ... and 11 more (see full listing online)

## Locations (1 total)

---

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China